Abiopharma

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

UGI Declares Common Dividend

Taboola to Participate in Upcoming Investor Conferences

Victory Capital Reports Record First Quarter Results

Cooper Standard Reports Solid First Quarter 2026 Results and Strong New Business Awards; Remains on Track to Achieve or Exceed Full Year Plans

PROG Holdings, Inc. Declares Dividend

Watts Water Technologies Reports Record First Quarter 2026 Results

argenx to Present at BofA Securities 2026 Health Care Conference

Host Hotels & Resorts, Inc. Reports Results for the First Quarter 2026

Bionano Announces Leadership Transition